Confirm delete?

Bertin Bioreagent
logo

Search

Contact Us
You are here :

From Metabolic Syndrome To Cachexia: What’S New About Metabolic Biomarkers ?

From metabolic syndrome to cachexia: what’s new about metabolic biomarkers ?

Date : Since 01/08/2019

Place : Montigny le Bretonneux

Bioreagents

written by Odile Viltart and Virginie Tolle, PhD - INSERM UMR894 – Centre de Psychiatrie et Neurosciences, Paris, FRANCE

Metabolic syndrome (MetS) is the constellation of risks namely abdominal obesity, insulin-resistance, type 2 diabetes, dyslipidemia and arterial hypertension.  In this article, our experts are reviewing a brief history of metabolic syndrome, the importance of biomarkers for the diagnosis and prognosis of nutritional/metabolic disorders and the challenge of identifying new biomarkers

Read the scientific publication >>

Top